21st Jul 2021 16:25
(Alliance News) - EKF Diagnostics Holdings PLC on Wednesday said it expects to report a full year performance in-line with expectations following a strong performance in the first half.
Shares in EKF Diagnostics were up 4.5% at 74.20 pence each in London on Wednesday afternoon.
Cardiff, Wales-based EKF Diagnostics is a medical manufacturer of point-of-care devices.
Revenue for the six months ended June 30 was GBP38.6 million, a rise of 47% year-on-year from GBP26.3 million.
Following the payment of an inaugural cash dividend of 1.0 pence per share at the end of last year, the company has confirmed its intention to maintain a progressive dividend policy, and a further dividend payment to shareholders of 1.1p per share.
Going forward, EKF Diagnostics remains confident in its strategy of investing in the existing core business to drive strong organic growth but also seeking complementary and targeted acquisitions with key strategic value to the core business, it said.
"The strong trading from the beginning of the year continued into the second quarter of 2021, reflecting the improving trading in the core business and ongoing strong demand for its contract manufacturing services for Covid-19 sample collection devices and associated kits. The board remains confident that trading for the full year will remain strong and will be in-line with already materially upgraded management expectations," the company said.
Results for the half are due in the first two weeks of September.
By Amrit Sahota; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Ekf Diagnostics